<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668236</url>
  </required_header>
  <id_info>
    <org_study_id>RH-ITA-007</org_study_id>
    <nct_id>NCT03668236</nct_id>
  </id_info>
  <brief_title>The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial</brief_title>
  <acronym>CLASSIC</acronym>
  <official_title>The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anders Perner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Research in Intensive Care (CRIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scandinavian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Scandinavian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess patient important benefits and harms of IV fluid
      restriction vs. standard care fluid therapy in patients with septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Septic shock is common, often lethal, costly, and associated with prolonged suffering among
      survivors and relatives. Traditionally, intravenous (IV) fluids are used to optimise the
      circulation, and the use of higher volumes is recommended by international guidelines. There
      is, however, no high-quality evidence to support this. In contrast, data from cohort studies,
      small trials and systematic reviews in sepsis and large trials in other settings and patient
      groups suggest potential benefits from restriction of IV fluids in patients with septic
      shock.

      OBJECTIVES:

      The aim of the CLASSIC trial is to assess the benefits and harms of IV fluid restriction vs.
      standard care on patient-important outcome measures in adult intensive care unit (ICU)
      patients with septic shock.

      DESIGN:

      CLASSIC is an international, multicentre, parallel-grouped, open-labelled, centrally
      randomised, stratified, outcome assessor- and analyst-blinded trial.

      POPULATION:

      Adult ICU patients who have septic shock and have received at least 1 L of IV fluid in the
      last 24-hours.

      EXPERIMENTAL INTERVENTION:

      In the IV fluid restriction group no IV fluids should be given in the ICU unless extenuating
      circumstances occur, including signs of severe hypoperfusion, overt fluid loss or a failing
      GI tract with a total fluid input of less than 1 L per day. In these circumstances, IV fluid
      may be given in measured amounts.

      CONTROL INTERVENTION:

      In the standard care group there will be no upper limit for the use of IV fluids.

      OUTCOMES:

      The primary outcome is 90-day mortality; secondary outcomes are serious adverse events in the
      ICU (ischemic events or severe acute kidney injury); days alive without life support at day
      90; days alive and out of hospital at day 90 and mortality, health-related quality of life
      and cognitive function at 1-year.

      TRIAL SIZE:

      A total of 1554 participants will be randomised to allow the detection of a 15% relative risk
      reduction (7% absolute) in the restrictive vs. standard care group in 90-day mortality with a
      power of 80%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor- and analyst-blinded trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Day 90 after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with one or more serious adverse events (SAEs) in the ICU defined as ischaemic events (cerebral, cardiac, intestinal or limb ischaemia) or as a new episode of severe acute kidney injury (modified KDIGO-3)</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with one or more serious adverse reactions (SARs) to IV crystalloids in the ICU.</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive at day 90 without life support (vasopressor / inotropic support, invasive mechanical ventilation or renal replacement therapy)</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital at day 90</measure>
    <time_frame>Day 90 after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 1-year after randomisation</measure>
    <time_frame>1-year after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life 1-year after randomisation</measure>
    <time_frame>1-year after randomisation</time_frame>
    <description>Will be measured using the EuroQoL EQ-5D-5L questionnaire (comprising 5 questions with a score from 1 to 5 each and a visual analogue scale from 0 to 100). Participants who have died will be assigned the lowest possible scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function 1-year after randomisation</measure>
    <time_frame>1-year after randomisation</time_frame>
    <description>Will be assessed by the Montreal Cognitive Assessment (MoCa) MINI score which is soon to be released. Participants who have died will be assigned the lowest possible score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1554</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Fluid restriction group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:
In case of severe hypoperfusion or severe circulatory impairment defined by either:
Lactate≥4 mmol/L
MAP&lt;50 mmHg (with or without vasopressor/inotrope)
Mottling beyond the kneecap (mottling score &gt;2) OR
Urinary output&lt;0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation
A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation
In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.
In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:
Correct dehydration or electrolyte deficiencies
Ensure a total fluid input of 1L per 24hrs
IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:
IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.
IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid
IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic crystalloids</intervention_name>
    <description>Types of fluid to be used in both intervention groups:
IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation
Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used
Fluids used for dehydration: Water or isotonic glucose should be used
Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia
Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy</description>
    <arm_group_label>Fluid restriction group</arm_group_label>
    <arm_group_label>Standard-care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All the following criteria must be fulfilled:

          -  Aged 18 years or above

          -  Admitted to the ICU or plan to be admitted to the ICU regardless of trial
             participation

          -  Septic shock defined according to the Sepsis-3 criteria:

               -  Suspected or confirmed site of infection or positive blood culture AND

               -  Ongoing infusion of vasopressor/inotrope agent to maintain a mean arterial blood
                  pressure of 65 mmHg or above AND

               -  Lactate of 2 mmol/L or above in any plasma sample performed within the last
                  3-hours

          -  Have received at least 1 L of IV fluid (crystalloids, colloids or blood products) in
             the last 24-hours prior to screening.

        Exclusion Criteria:

        Patients who fulfil any of the following criteria will be excluded:

          -  Septic shock for more than 12 hours at the time of screening as these patients are no
             longer early in their course

          -  Life-threatening bleeding as these patients need specific fluid/blood product
             strategies

          -  Acute burn injury of more than 10% of the body surface area as these patients need a
             specific fluid strategy

          -  Known pregnancy

          -  Consent not obtainable as per the model approved for the specific site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tine Sylvest Meyhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Perner, MD PhD</last_name>
    <phone>+4535458333</phone>
    <email>anders.perner@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tine Sylvest Meyhoff, MD</last_name>
    <phone>+4535450606</phone>
    <email>classic@cric.nu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brussels (UZB)</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manu Malbrain</last_name>
      <email>Manu.Malbrain@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit, Fakultni Nemocnice</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Nalos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark.</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bodil S Rasmussen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Intensive Care,Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Sylvest Meyhoff, MD</last_name>
      <phone>+45 3545 0606</phone>
      <email>classic@cric.nu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Søren Hoffmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Gyldensted, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Copenhagen University Hospital Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Christensen, MD</last_name>
      <email>Henrik.Christensen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rasmussen, MD</last_name>
    </contact>
    <contact_backup>
      <email>Michael.Lindhardt.Rasmussen@vest.rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Bestle, MD</last_name>
      <email>morten.bestle@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Lillebaelt Hospital</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Craveiro Brochner, MD</last_name>
      <email>Anne.Craveiro.Broechner@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Køge</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Nebrich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Randers Hospital</name>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Vang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hildebrandt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Klaus Vennick Marcussen,, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Intensive Care, Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoffer Sølling, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland.</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ville Pettilä, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, Hôpital St. Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Darmon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas research hospital Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Albano, MD</last_name>
      <email>giovanni.albano@gavazzeni.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Humanitas Research Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Cecconi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iwan van der Horst, MD, PhD</last_name>
      <email>i.c.c.van.der.horst@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of intensive care, Østfold, Kalnes</name>
      <address>
        <city>Grålum</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Karin Martin, MD</last_name>
      <email>Yvonne.Karin.Martin@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of intensive Care, Innlandet Hamar</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bror Johnstad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Henrik Laake, MD</last_name>
      <email>jon.henrik.laake@rikshospitalet.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Ferrer Roca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of intensive care, Huddinge</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ahlstedt, MD</last_name>
      <email>christian.ahlstedt@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Solna</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Mårtensson, MD</last_name>
      <email>johan.martensson@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical ICU, Karolinska, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Hollenberg, MD</last_name>
      <email>jacob.hollenberg@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cronhjort, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Cronhjort, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of intensive care, Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Siegemund</last_name>
      <email>Martin.Siegemund@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan M Jakob, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.cric.nu/classic/</url>
    <description>Official study website</description>
  </link>
  <reference>
    <citation>Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilä V, Aaen A, Lodahl D, Berthelsen RE, Christensen H, Madsen MB, Winkel P, Wetterslev J, Perner A; CLASSIC Trial Group; Scandinavian Critical Care Trials Group. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med. 2016 Nov;42(11):1695-1705. Epub 2016 Sep 30.</citation>
    <PMID>27686349</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Scandinavian Critical Care Trials Group</investigator_affiliation>
    <investigator_full_name>Anders Perner</investigator_full_name>
    <investigator_title>MD, PhD, Senior staff specialist , Professor in Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Fluid resuscitation</keyword>
  <keyword>Critical care</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Crystalloid</keyword>
  <keyword>IV fluid therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

